CTLA4 and neoplasm: This systemic immune response affecting the left flank tumor was stronger than when mice with a small left flank tumor received systemic srIL-2 and anti-CTLA-4, together with RT and subcutaneous IL-12 given to the skin on the distant right flank, in mice not bearing a tumor in the right flank (Supplementary Figure 2C).